The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells
Open accessAbstract
Regulatory T cells (T reg cells) play a major role in controlling the pathogenic autoimmune process in type 1 diabetes (T1D). Interleukin 2 (IL-2), a cytokine which promotes T reg cell survival and function, may thus have therapeutic efficacy in T1D. We show that 5 d of low-dose IL-2 administration starting at the time of T1D onset can reverse established disease in NOD (nonobese diabetic) mice, with long-lasting effects. Low-dose IL-2 increases the number of T reg cells in the pancreas and induces expression of T reg cell–associated proteins including Foxp3, CD25, CTLA-4, ICOS (inducible T cell costimulator), and GITR (glucocorticoid-induced TNF receptor) in these cells. Treatment also suppresses interferon γ production by pancreas-infiltrating T cells. Transcriptome analyses show that low-dose IL-2 exerts much greater influence on gene expression of T reg cells than effector T cells (T eff cells), suggesting that nonspecific activation of pathogenic T eff cells is less likely. We provide the first preclinical data showing that low-dose IL-2 can reverse established T1D, suggesting that this treatment merits evaluation in patients with T1D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 2×
“This approach has been tested in a clinical trial using agonistic -CD28 (Suntharalingam et al., 2006) and in preclinical models with high doses of IL-2, IL-2/–IL-2 complex, or Flt3-L (Swee et al.”
MethodSalomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,081
Self-citationUlcerative colitis-like disease in mice with a disrupted interleukin-2 gene
Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A. C., & Horak, I. (1993) · Cell · doi:10.1016/0092-8674(93)80067-o · Cited by 1,744
Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease
Sakaguchi, S., Ono, M., Setoguchi, R., Yagi, H., Hori, S., Fehervari, Z., Shimizu, J., Takahashi, T., & Nomura, T. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00427.x · Cited by 1,555
Zhou, X., Bailey-Bucktrout, S. L., Jeker, L. T., Penaranda, C., Martínez-Llordella, M., Ashby, M., Nakayama, M., Rosenthal, W., & Bluestone, J. A. (2009) · Nature Immunology · doi:10.1038/ni.1774 · Cited by 1,370
Self-citationIn Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes
Tang, Q., Henriksen, K. J., Bi, M., Finger, E. B., Szot, G., Ye, J., Masteller, E. L., McDevitt, H., Bonyhadi, M., & Bluestone, J. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040139 · Cited by 1,221
Self-citationRapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells
Battaglia, M., Stabilini, A., & Roncarolo, M.-G. (2005) · Blood · doi:10.1182/blood-2004-10-3932 · Cited by 1,134
Malek, T. R. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090357 · Cited by 1,079
Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction
Tang, Q., Adams, J. Y., Penaranda, C., Melli, K., Piaggio, E., Sgouroudis, E., Piccirillo, C. A., Salomon, B. L., & Bluestone, J. A. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.016 · Cited by 729
Self-citationIL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients
Ahmadzadeh, M., & Rosenberg, S. A. (2006) · Blood · doi:10.1182/blood-2005-06-2399 · Cited by 632
Cited by
Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
Saadoun, D., Rosenzwajg, M., Joly, F., Six, A., Carrat, F., Thibault, V., Sene, D., Cacoub, P., & Klatzmann, D. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105143 · Cited by 762
Self-citationTreg cell-based therapies: challenges and perspectives
Raffin, C., Vo, L. T., & Bluestone, J. A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0232-6 · Cited by 720
Self-citationBiology and regulation of IL-2: from molecular mechanisms to human therapy
Spolski, R., Li, P., & Leonard, W. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0046-y · Cited by 637
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
Klatzmann, D., & Abbas, A. K. (2015) · Nature Reviews Immunology · doi:10.1038/nri3823 · Cited by 636
Self-citationGATA3 controls Foxp3+ regulatory T cell fate during inflammation in mice
Wohlfert, E. A., Grainger, J. R., Bouladoux, N., Konkel, J. E., Oldenhove, G., Ribeiro, C. H., Hall, J. A., Yagi, R., Naik, S., Bhairavabhotla, R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57456 · Cited by 556
Ballesteros-Tato, A., León, B., Graf, B. A., Moquin, A., Adams, P. S., Lund, F. E., & Randall, T. D. (2012) · Immunity · doi:10.1016/j.immuni.2012.02.012 · Cited by 542
Hartemann, A., Bensimon, G., Payan, C. A., Jacqueminet, S., Bourron, O., Nicolas, N., Fonfrede, M., Rosenzwajg, M., Bernard, C., & Klatzmann, D. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70113-x · Cited by 428
Self-citationCell-cell communication: New insights and clinical implications
Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433
From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines
Banchereau, J., Pascual, V., & O'Garra, A. (2012) · Nature Immunology · doi:10.1038/ni.2406 · Cited by 401
Bailey-Bucktrout, S. L., Martinez-Llordella, M., Zhou, X., Anthony, B., Rosenthal, W., Luche, H., Fehling, H. J., & Bluestone, J. A. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.016 · Cited by 396
Self-citationBour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391
Self-citationRegulatory T cells delay disease progression in Alzheimer-like pathology
Dansokho, C., Ait Ahmed, D., Aid, S., Toly-Ndour, C., Chaigneau, T., Calle, V., Cagnard, N., Holzenberger, M., Piaggio, E., Aucouturier, P., et al. (2016) · Brain · doi:10.1093/brain/awv408 · Cited by 359
Self-citationBurrack, A. L., Martinov, T., & Fife, B. T. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00343 · Cited by 330
Long, S. A., Rieck, M., Sanda, S., Bollyky, J. B., Samuels, P. L., Goland, R., Ahmann, A., Rabinovitch, A., Aggarwal, S., Phippard, D., et al. (2012) · Diabetes · doi:10.2337/db12-0049 · Cited by 314
Self-citationRegulatory T cells in the treatment of disease
Sharabi, A., Tsokos, M. G., Ding, Y., Malek, T. R., Klatzmann, D., & Tsokos, G. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.148 · Cited by 297
Self-citationDual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy
Bhattacharya, P., Budnick, I., Singh, M., Thiruppathi, M., Alharshawi, K., Elshabrawy, H., Holterman, M. J., & Prabhakar, B. S. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0149 · Cited by 264
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients
Rosenzwajg, M., Churlaud, G., Mallone, R., Six, A., Dérian, N., Chaara, W., Lorenzon, R., Long, S. A., Buckner, J. H., Afonso, G., et al. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.01.001 · Cited by 257
Self-citationType 1 diabetes: translating mechanistic observations into effective clinical outcomes
Herold, K. C., Vignali, D. A. A., Cooke, A., & Bluestone, J. A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3422 · Cited by 237
Self-citationRegulatory T cell dysfunction in type 1 diabetes: what's broken and how can we fix it?
Hull, C. M., Peakman, M., & Tree, T. I. M. (2017) · Diabetologia · doi:10.1007/s00125-017-4377-1 · Cited by 194
T cells in the control of organ-specific autoimmunity
Bluestone, J. A., Bour-Jordan, H., Cheng, M., & Anderson, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78089 · Cited by 155
Self-citationMingozzi, F., Chen, Y., Murphy, S. L., Edmonson, S. C., Tai, A., Price, S. D., Metzger, M. E., Zhou, S., Wright, J. F., Donahue, R. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.84 · Cited by 112
Parent, A. V., Faleo, G., Chavez, J., Saxton, M., Berrios, D. I., Kerper, N. R., Tang, Q., & Hebrok, M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109538 · Cited by 96
“…Keir et al., 2006; Wang et al., 2008) while strategies that promote endogenous regulatory T cells (Treg cells) or direct infusion of Treg cells can reverse autoimmune diabetes and prevent rejection of transplanted islets in mice (Grinberg-Bleyer et al., 2010; Lee et al., 2014; Tang et al., 2004).”
Self-citationStanford, S. M., Krishnamurthy, D., Falk, M. D., Messina, R., Debnath, B., Li, S., Liu, T., Kazemi, R., Dahl, R., He, Y., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101202j · Cited by 59
The Non-Obese Diabetic (NOD) Mouse as a Model of Human Type 1 Diabetes
Kachapati, K., Adams, D., Bednar, K., & Ridgway, W. M. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-62703-068-7_1 · Cited by 54
Combination immunotherapy for type 1 diabetes
Bone, R. N., & Evans-Molina, C. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0878-z · Cited by 41
Metadata
- Authors
- Grinberg-Bleyer, Y., Baeyens, A., You, S., Elhage, R., Fourcade, G., Gregoire, S., Cagnard, N., Carpentier, W., Tang, Q., Bluestone, J., Chatenoud, L., Klatzmann, D., Salomon, B. L., & Piaggio, E.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-08-02
- Volume
- 207
- Issue
- 9
- Pages
- 1871-1878
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2126897233
- Cited by
- 433
- References
- 30
- FWCI
- 17.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.